Literature DB >> 3875363

Increased anaphylatoxins (C3a and C4a) in psoriatic sera.

K Ohkohchi, H Takematsu, H Tagami.   

Abstract

We measured C3a and C4a anaphylatoxins in the serum of 56 psoriatic patients and 36 healthy control subjects by radioimmunoassay in order to clarify the mechanism of complement activation occurring in psoriatic lesions. Whereas a small amount of anaphylatoxins were demonstrable even in the sera of healthy adults, the serum concentrations of C3a and C4a anaphylatoxins were significantly higher in psoriatic patients than those in non-psoriatic controls. The increased serum anaphylatoxin levels did not correlate well with either the extent or the activity of the skin lesions, but a comparison of anaphylatoxin levels in 10 patients before and after successful treatment of skin lesions showed that the serum anaphylatoxin levels decreased with improvement of the skin lesions. Our results suggest that complement activation takes place in psoriatic patients chiefly via the classical pathway.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3875363     DOI: 10.1111/j.1365-2133.1985.tb02064.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  4 in total

1.  Soluble interleukin-2 receptors and psoriasis.

Authors:  R Dummer; F G Dunkel
Journal:  Arch Dermatol Res       Date:  1991       Impact factor: 3.017

2.  Correlation between HLA-A2-Bw46-DRw8 haplotype and increased levels of complement components (C4 and C4a) in patients with psoriatic arthritis.

Authors:  M Muto; M Mashimo; K Urabe; T Suzuki; T Sasazuki
Journal:  Arch Dermatol Res       Date:  1991       Impact factor: 3.017

Review 3.  The role of complement-derived mediators in inflammatory skin diseases.

Authors:  H Tagami
Journal:  Arch Dermatol Res       Date:  1992       Impact factor: 3.017

Review 4.  Complement Activation in Inflammatory Skin Diseases.

Authors:  Jenny Giang; Marc A J Seelen; Martijn B A van Doorn; Robert Rissmann; Errol P Prens; Jeffrey Damman
Journal:  Front Immunol       Date:  2018-04-16       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.